JP2002511070A

JP2002511070A - ヒト腫瘍壊死因子受容体ｔｒ１０

ヒト腫瘍壊死因子受容体ｔｒ１０

Info

Publication number: JP2002511070A
Authority: JP; Japan
Prior art keywords: polypeptide; amino acid; sequence; receptor; seq
Prior art date: 1997-05-30
Legal status : Withdrawn

Application number

JP50095499A

Other languages

English (en)

Japanese (ja)

Other versions

JP2002511070A5 (enExample

Inventor

ニ，ジアン

エイ．ローゼン，クレイグ

Original Assignee

ヒューマンジノームサイエンシーズ，インコーポレイテッド

Priority date

1997-05-30

Filing date

1998-05-29

Publication date

2002-04-09

1998-05-29 Application filed by ヒューマンジノームサイエンシーズ，インコーポレイテッド filed Critical ヒューマンジノームサイエンシーズ，インコーポレイテッド

2002-04-09 Publication of JP2002511070A publication Critical patent/JP2002511070A/ja

2005-12-08 Publication of JP2002511070A5 publication Critical patent/JP2002511070A5/ja

Status Withdrawn legal-status Critical Current

Links

108020003175 receptors Proteins 0.000 title claims abstract description 132
102000005962 receptors Human genes 0.000 title claims abstract description 128
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 title description 3
102000057041 human TNF Human genes 0.000 title description 3
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 212
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 194
229920001184 polypeptide Polymers 0.000 claims abstract description 185
238000000034 method Methods 0.000 claims abstract description 82
150000007523 nucleic acids Chemical class 0.000 claims abstract description 75
102000039446 nucleic acids Human genes 0.000 claims abstract description 64
108020004707 nucleic acids Proteins 0.000 claims abstract description 64
239000013598 vector Substances 0.000 claims abstract description 38
239000000556 agonist Substances 0.000 claims abstract description 32
239000005557 antagonist Substances 0.000 claims abstract description 28
238000010188 recombinant method Methods 0.000 claims abstract description 4
210000004027 cell Anatomy 0.000 claims description 160
239000002773 nucleotide Chemical group 0.000 claims description 100
125000003729 nucleotide group Chemical group 0.000 claims description 99
125000003275 alpha amino acid group Chemical group 0.000 claims description 73
150000001413 amino acids Chemical class 0.000 claims description 62
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 56
239000002299 complementary DNA Substances 0.000 claims description 56
230000006907 apoptotic process Effects 0.000 claims description 43
102000040430 polynucleotide Human genes 0.000 claims description 40
108091033319 polynucleotide Proteins 0.000 claims description 40
239000002157 polynucleotide Substances 0.000 claims description 40
125000000539 amino acid group Chemical group 0.000 claims description 34
108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
230000027455 binding Effects 0.000 claims description 21
102000010170 Death domains Human genes 0.000 claims description 20
108050001718 Death domains Proteins 0.000 claims description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 18
230000001965 increasing effect Effects 0.000 claims description 18
230000003834 intracellular effect Effects 0.000 claims description 18
238000006467 substitution reaction Methods 0.000 claims description 15
230000000295 complement effect Effects 0.000 claims description 13
238000009396 hybridization Methods 0.000 claims description 9
230000036961 partial effect Effects 0.000 claims description 5
210000003370 receptor cell Anatomy 0.000 claims description 5
208000027866 inflammatory disease Diseases 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
238000012258 culturing Methods 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
108010076039 Polyproteins Proteins 0.000 claims 1
208000037765 diseases and disorders Diseases 0.000 claims 1
230000000717 retained effect Effects 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 132
102000004169 proteins and genes Human genes 0.000 abstract description 95
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 51
230000000694 effects Effects 0.000 abstract description 23
241000282414 Homo sapiens Species 0.000 abstract description 21
238000012216 screening Methods 0.000 abstract description 12
102000003390 tumor necrosis factor Human genes 0.000 abstract description 3
108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 abstract description 2
102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 abstract description 2
235000018102 proteins Nutrition 0.000 description 90
239000003446 ligand Substances 0.000 description 59
235000001014 amino acid Nutrition 0.000 description 52
108020004414 DNA Proteins 0.000 description 51
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 48
230000014509 gene expression Effects 0.000 description 48
229940024606 amino acid Drugs 0.000 description 43
239000012634 fragment Substances 0.000 description 40
150000001875 compounds Chemical class 0.000 description 33
210000001519 tissue Anatomy 0.000 description 31
108700012411 TNFSF10 Proteins 0.000 description 28
102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 28
101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 26
239000013615 primer Substances 0.000 description 25
239000013612 plasmid Substances 0.000 description 24
230000036755 cellular response Effects 0.000 description 22
238000003556 assay Methods 0.000 description 21
238000004458 analytical method Methods 0.000 description 18
238000012217 deletion Methods 0.000 description 17
230000037430 deletion Effects 0.000 description 17
201000010099 disease Diseases 0.000 description 17
230000035772 mutation Effects 0.000 description 17
238000003752 polymerase chain reaction Methods 0.000 description 16
108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 15
238000010367 cloning Methods 0.000 description 15
102000003298 tumor necrosis factor receptor Human genes 0.000 description 15
230000001404 mediated effect Effects 0.000 description 14
108091026890 Coding region Proteins 0.000 description 13
210000001744 T-lymphocyte Anatomy 0.000 description 13
206010028980 Neoplasm Diseases 0.000 description 12
241000588724 Escherichia coli Species 0.000 description 11
230000000890 antigenic effect Effects 0.000 description 11
210000000349 chromosome Anatomy 0.000 description 11
238000003776 cleavage reaction Methods 0.000 description 11
238000005516 engineering process Methods 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
230000007017 scission Effects 0.000 description 11
230000011664 signaling Effects 0.000 description 11
208000030507 AIDS Diseases 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
241000700605 Viruses Species 0.000 description 10
108020001507 fusion proteins Proteins 0.000 description 10
102000037865 fusion proteins Human genes 0.000 description 10
239000002609 medium Substances 0.000 description 10
238000000746 purification Methods 0.000 description 10
239000000523 sample Substances 0.000 description 10
102000053602 DNA Human genes 0.000 description 9
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 9
230000004913 activation Effects 0.000 description 9
238000001514 detection method Methods 0.000 description 9
239000013604 expression vector Substances 0.000 description 9
239000003550 marker Substances 0.000 description 9
229960000485 methotrexate Drugs 0.000 description 9
239000000243 solution Substances 0.000 description 9
238000013518 transcription Methods 0.000 description 9
230000035897 transcription Effects 0.000 description 9
238000013519 translation Methods 0.000 description 9
-1 4-1B Includes BL Proteins 0.000 description 8
108020004705 Codon Proteins 0.000 description 8
101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 8
101150064015 FAS gene Proteins 0.000 description 8
101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 8
230000030833 cell death Effects 0.000 description 8
210000000987 immune system Anatomy 0.000 description 8
239000000203 mixture Substances 0.000 description 8
230000008488 polyadenylation Effects 0.000 description 8
108091008146 restriction endonucleases Proteins 0.000 description 8
102000004127 Cytokines Human genes 0.000 description 7
108090000695 Cytokines Proteins 0.000 description 7
241000701022 Cytomegalovirus Species 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
102100026693 FAS-associated death domain protein Human genes 0.000 description 7
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 7
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 7
239000011543 agarose gel Substances 0.000 description 7
230000001580 bacterial effect Effects 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
230000004927 fusion Effects 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
210000004072 lung Anatomy 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
230000003248 secreting effect Effects 0.000 description 7
241000701447 unidentified baculovirus Species 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
238000001712 DNA sequencing Methods 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
241000238631 Hexapoda Species 0.000 description 6
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
101150009046 Tnfrsf1a gene Proteins 0.000 description 6
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 6
238000007792 addition Methods 0.000 description 6
229960000723 ampicillin Drugs 0.000 description 6
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
230000006870 function Effects 0.000 description 6
239000000499 gel Substances 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
210000004962 mammalian cell Anatomy 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
229960004452 methionine Drugs 0.000 description 6
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 6
230000008569 process Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
238000012163 sequencing technique Methods 0.000 description 6
101150074155 DHFR gene Proteins 0.000 description 5
101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 5
238000000636 Northern blotting Methods 0.000 description 5
230000003321 amplification Effects 0.000 description 5
230000002759 chromosomal effect Effects 0.000 description 5
210000002889 endothelial cell Anatomy 0.000 description 5
229960004198 guanidine Drugs 0.000 description 5
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
230000019491 signal transduction Effects 0.000 description 5
210000000813 small intestine Anatomy 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
238000001890 transfection Methods 0.000 description 5
108020005544 Antisense RNA Proteins 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 4
108010039471 Fas Ligand Protein Proteins 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
108090000542 Lymphotoxin-alpha Proteins 0.000 description 4
108010025020 Nerve Growth Factor Proteins 0.000 description 4
102000015336 Nerve Growth Factor Human genes 0.000 description 4
108700026244 Open Reading Frames Proteins 0.000 description 4
108010076504 Protein Sorting Signals Proteins 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
239000003184 complementary RNA Substances 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
210000003527 eukaryotic cell Anatomy 0.000 description 4
102000018823 fas Receptor Human genes 0.000 description 4
230000001605 fetal effect Effects 0.000 description 4
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
108020001756 ligand binding domains Proteins 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
229940053128 nerve growth factor Drugs 0.000 description 4
210000001672 ovary Anatomy 0.000 description 4
230000002018 overexpression Effects 0.000 description 4
125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 4
238000003127 radioimmunoassay Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
241001430294 unidentified retrovirus Species 0.000 description 4
108020004491 Antisense DNA Proteins 0.000 description 3
101150013553 CD40 gene Proteins 0.000 description 3
102100038385 Coiled-coil domain-containing protein R3HCC1L Human genes 0.000 description 3
206010052360 Colorectal adenocarcinoma Diseases 0.000 description 3
206010061819 Disease recurrence Diseases 0.000 description 3
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000009329 Graft vs Host Disease Diseases 0.000 description 3
208000031886 HIV Infections Diseases 0.000 description 3
208000037357 HIV infectious disease Diseases 0.000 description 3
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
206010058467 Lung neoplasm malignant Diseases 0.000 description 3
102000004083 Lymphotoxin-alpha Human genes 0.000 description 3
206010040070 Septic Shock Diseases 0.000 description 3
108010022394 Threonine synthase Proteins 0.000 description 3
206010052779 Transplant rejections Diseases 0.000 description 3
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 3
102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 3
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 3
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
239000003816 antisense DNA Substances 0.000 description 3
238000003782 apoptosis assay Methods 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000031018 biological processes and functions Effects 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
238000004590 computer program Methods 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
102000004419 dihydrofolate reductase Human genes 0.000 description 3
239000012636 effector Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
108010052621 fas Receptor Proteins 0.000 description 3
235000013350 formula milk Nutrition 0.000 description 3
208000024908 graft versus host disease Diseases 0.000 description 3
230000012010 growth Effects 0.000 description 3
210000003917 human chromosome Anatomy 0.000 description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
230000002519 immonomodulatory effect Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
229930027917 kanamycin Natural products 0.000 description 3
229960000318 kanamycin Drugs 0.000 description 3
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
229930182823 kanamycin A Natural products 0.000 description 3
210000002510 keratinocyte Anatomy 0.000 description 3
230000002147 killing effect Effects 0.000 description 3
238000002372 labelling Methods 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
230000006654 negative regulation of apoptotic process Effects 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
230000005522 programmed cell death Effects 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
230000010076 replication Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
241000894007 species Species 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102100027207 CD27 antigen Human genes 0.000 description 2
108010029697 CD40 Ligand Proteins 0.000 description 2
102100032937 CD40 ligand Human genes 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
102000004091 Caspase-8 Human genes 0.000 description 2
108090000538 Caspase-8 Proteins 0.000 description 2
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
230000004544 DNA amplification Effects 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
241001131785 Escherichia coli HB101 Species 0.000 description 2
108010077716 Fas-Associated Death Domain Protein Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
101710154606 Hemagglutinin Proteins 0.000 description 2
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
101000743767 Homo sapiens Coiled-coil domain-containing protein R3HCC1L Proteins 0.000 description 2
101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
108010054278 Lac Repressors Proteins 0.000 description 2
201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
102000003945 NF-kappa B Human genes 0.000 description 2
108010057466 NF-kappa B Proteins 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
101710182846 Polyhedrin Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
101710176177 Protein A56 Proteins 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000005860 defense response to virus Effects 0.000 description 2
229960002086 dextran Drugs 0.000 description 2
229960000633 dextran sulfate Drugs 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
239000000539 dimer Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000008482 dysregulation Effects 0.000 description 2
230000005014 ectopic expression Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
235000019688 fish Nutrition 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
208000037906 ischaemic injury Diseases 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
239000000463 material Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
210000003574 melanophore Anatomy 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000031864 metaphase Effects 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
210000000287 oocyte Anatomy 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000006461 physiological response Effects 0.000 description 2
230000004983 pleiotropic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
108010066381 preproinsulin Proteins 0.000 description 2
239000002987 primer (paints) Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
108700015048 receptor decoy activity proteins Proteins 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
239000006152 selective media Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
238000001262 western blot Methods 0.000 description 2
238000001086 yeast two-hybrid system Methods 0.000 description 2
LWAVGNJLLQSNNN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-azidobenzoate Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C(=O)ON1C(=O)CCC1=O LWAVGNJLLQSNNN-UHFFFAOYSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical group CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
FMYBFLOWKQRBST-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]acetic acid;nickel Chemical compound [Ni].OC(=O)CN(CC(O)=O)CC(O)=O FMYBFLOWKQRBST-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
241000701386 African swine fever virus Species 0.000 description 1
101100216424 African swine fever virus (strain E-70 MS44) LMW5-HL gene Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
102220547881 Apoptosis-associated speck-like protein containing a CARD_D50R_mutation Human genes 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
101150013616 BHRF1 gene Proteins 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010046080 CD27 Ligand Proteins 0.000 description 1
102100025221 CD70 antigen Human genes 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010063094 Cerebral malaria Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
238000000116 DAPI staining Methods 0.000 description 1
102000009058 Death Domain Receptors Human genes 0.000 description 1
108010049207 Death Domain Receptors Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000971521 Homo sapiens Kinetochore scaffold 1 Proteins 0.000 description 1
101100425753 Homo sapiens TNFRSF1A gene Proteins 0.000 description 1
101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
101100122503 Human herpesvirus 6A (strain Uganda-1102) gN gene Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
241000519695 Ilex integra Species 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
102100021464 Kinetochore scaffold 1 Human genes 0.000 description 1
101100288095 Klebsiella pneumoniae neo gene Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
101710192602 Latent membrane protein 1 Proteins 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
108090000362 Lymphotoxin-beta Proteins 0.000 description 1
102100026894 Lymphotoxin-beta Human genes 0.000 description 1
108091027974 Mature messenger RNA Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100278853 Mus musculus Dhfr gene Proteins 0.000 description 1
101100537545 Mus musculus Fas gene Proteins 0.000 description 1
101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 description 1
101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
101100537948 Mus musculus Trir gene Proteins 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
108091008604 NGF receptors Proteins 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
241001045988 Neogene Species 0.000 description 1
101100007739 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) crmA gene Proteins 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108010042215 OX40 Ligand Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
101150084935 PTER gene Proteins 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
208000007014 Retinitis pigmentosa Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
108091058545 Secretory proteins Proteins 0.000 description 1
102000040739 Secretory proteins Human genes 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
230000004308 accommodation Effects 0.000 description 1
239000000061 acid fraction Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
239000003098 androgen Substances 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003491 array Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000028956 calcium-mediated signaling Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
108010079785 calpain inhibitors Proteins 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
101150055276 ced-3 gene Proteins 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
238000003200 chromosome mapping Methods 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
210000003027 ear inner Anatomy 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
229940014144 folate Drugs 0.000 description 1
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
230000003325 follicular Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
108060003196 globin Proteins 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000006451 grace's insect medium Substances 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
238000012188 high-throughput screening assay Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
102000052073 human NGFR Human genes 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000028993 immune response Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000010249 in-situ analysis Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
230000030214 innervation Effects 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
101150109249 lacI gene Proteins 0.000 description 1
239000002523 lectin Substances 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000004457 myocytus nodalis Anatomy 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
238000010915 one-step procedure Methods 0.000 description 1
230000005868 ontogenesis Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
239000000668 oral spray Substances 0.000 description 1
229940041678 oral spray Drugs 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000037361 pathway Effects 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
238000005222 photoaffinity labeling Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
108020003519 protein disulfide isomerase Proteins 0.000 description 1
238000001799 protein solubilization Methods 0.000 description 1
230000007925 protein solubilization Effects 0.000 description 1
239000012264 purified product Substances 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003716 rejuvenation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000011435 rock Substances 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000036332 sexual response Effects 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
230000009131 signaling function Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000004513 sizing Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000009331 sowing Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229910052713 technetium Inorganic materials 0.000 description 1
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000013638 trimer Substances 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
239000000717 tumor promoter Substances 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1